Stockhead's Health and Biotech reporter Nadine McGrath is joined by industry experts to discuss healthcare and biotechnology investments.
Hear insights from leaders, innovators, and investors who are shaping the future of healthcare.
Whether you're an investor looking for the next big opportunity, a professional in the field, or simply curious about the advancements transforming healthcare, Vital Signs provides valuable insights and fascinating information.
Hear about cutting-edge technologies, groundbreaking research, and the financial strategies driving success in the biotech world.
Subscribe now to be a part of the exciting landscape of health and biotech investment.
In this episode, Nadine speaks to EZZ Life Science Chief Strategy Officer Glenn Cross. He discusses the company’s expanding health and wellness business across Australia and international markets. He covers its retail strategy, global partnerships, US expansion, new product ranges, scientific research and the opportunities emerging across changing consumer health and wellness trends.
Learn more about your ad choices. Visit megaphone.fm/adchoices
28 Aug 2026
Inside Prescient Therapeutics' fight against a rare blood cancer
Stockhead's Vital Signs sits down with Prescient Therapeutics (ASX:PTX) CEO James McDonnell to unpack PTX-100, a first-in-class cancer therapy targeting the RAS pathway implicated in 22% of cancers.
From the science behind the drug to its phase two trial in cutaneous T-cell lymphoma, a $580 million validating licensing deal, and the milestones ahead, McDonnell breaks down what investors should be watching next.
Learn more about your ad choices. Visit megaphone.fm/adchoices
9 Mar 2026
MASTRR study redefining regenerative healing - Aroa Biosurgery (ASX:ARX)
In today's episode, Nadine speaks to Dr. Adam Young of Aroa Biosurgery (ASX:ARX)
Learn more about your ad choices. Visit megaphone.fm/adchoices
9 Mar 2026
Vital Signs Podcast: Health Food Symmetry
In today's episode, Nadine speaks to Gordon Edwards, CEO of Health Food Symmetry
Learn more about your ad choices. Visit megaphone.fm/adchoices
21 Oct 2025
Redefining hearing health with personalised sound technology-Audeara (ASX:AUA)
In today's episode, Nadine speaks to Dr. James Fielding, CEO of Audeara (ASX:AUA)
Learn more about your ad choices. Visit megaphone.fm/adchoices
1 Jul 2025
Prescient eyes FDA fast track for cancer drug treatment | Prescient Therapeutics (ASX:PTX)
In today's episode, Nadine speaks to James McDonnell, CEO of Prescient Therapeutics (ASX:PTX)
Learn more about your ad choices. Visit megaphone.fm/adchoices
15 Jun 2025
Heartfelt & WiSE: EBR embarks on new growth chapter after US FDA approval
In today's episode, Nadine speaks to John McCutcheon President & CEO of EBR Systems (ASX:EBR)
Learn more about your ad choices. Visit megaphone.fm/adchoices
In today's episode, Nadine speaks to Gordon Haid, Global Neuro-Imaging Business Director of Compumedics (ASX:CMP)
Learn more about your ad choices. Visit megaphone.fm/adchoices
25 Mar 2025
Clever Culture Systems' shift to big pharma clients is perfect prescription - Clever Culture Systems (ASX:CC5)
In today's episode, Nadine speaks to Brent Barnes,
CEO and Managing Director of Clever Culture Systems (ASX:CC5)
Learn more about your ad choices. Visit megaphone.fm/adchoices
27 Feb 2025
Pioneering Pathology's Digital Future - Optiscan (ASX:OIL)
In today's episode, Nadine speaks to Dr Camile Farah, CEO of Optiscan (ASX:OIL)
Learn more about your ad choices. Visit megaphone.fm/adchoices
5 Feb 2025
"A global giant recognised our innovation" - Wellnex Life (ASX:WNX)
In today's episode, Nadine speaks to Zack Bozinovski, Executive Director of Wellnex Life (ASX:WNX).
Learn more about your ad choices. Visit megaphone.fm/adchoices
14 Jan 2025
"Unlocking regenerative medicine for everybody" - Aroa Biosurgery (ASX:ARX)
In today's episode, Nadine speaks to Dr. Adam Young, Vice President of Medical Affairs at Aroa Biosurgery (ASX:ARX).
Learn more about your ad choices. Visit megaphone.fm/adchoices
4 Aug 2024
"We want to become a dominant figure in wound care" - Aroa Biosurgery (ASX:ARX) | Vital Signs
In today's episode, Nadine speaks to James Agnew, CFO of Aroa Biosurgery (ASX:ARX) to discuss New Zealand's history of medical advancements and how Aroa is looking to become a world leader in wound care. After listing in 2020, Aroa is building from the original discoveries made by Dr. Brian Ward, using the forestomach of sheep to create a tissue scaffold assisting with chronic wound care, hernia repair and breast reconstruction among other conditions. James also gives us details on the company's current financial position and what the next 3-5 years looks like for growth.
Learn more about your ad choices. Visit megaphone.fm/adchoices
In today's episode, Nadine speaks to Dr Camile Farah, CEO of Optiscan (ASX:OIL) to discuss the fascinating history of the real time frozen section, breakthrough discoveries in pathology and how Optiscan is partnering with the world-renowned Mayo Clinic to develop technologies for safer and less intrusive procedures.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Contact Stockhead Presents: Vital Signs
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Stockhead Presents: Vital Signs?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
